{"id":"W4408161023","doi":"10.1038/s41591-025-03566-1","title":"Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute; U.S. Department of Health and Human Services","keywords":"Pembrolizumab; Oncology; Endometrial cancer; Medicine; Internal medicine; Randomized controlled trial; Chemotherapy; Cancer; Overall survival; Gynecology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009434521,0.000329457,0.002165596,0.0006343246,0.00005785174,0.000006946235,0.0001929953,0.0002887826,0.0004234552],"category_scores_gemma":[0.004598712,0.0001562609,0.0002818892,0.002181024,0.0003697211,0.00006487401,0.00006197504,0.000742868,4.033495e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003539065,"about_ca_system_score_gemma":0.0005681721,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003753091,"about_ca_topic_score_gemma":0.0002029568,"domain_scores_codex":[0.997224,0.0004026985,0.0008855379,0.0004451711,0.0007492573,0.0002932886],"domain_scores_gemma":[0.997183,0.001761208,0.000326377,0.0003947307,0.0001975231,0.0001371804],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9534906,0.000519292,0.0002216829,0.0001885705,0.0005849319,0.00001832424,0.0002350454,0.000003311407,0.002203972,0.0002227785,0.000475133,0.04183637],"study_design_scores_gemma":[0.9841709,0.001999749,0.0006525593,0.0009463684,0.000892443,0.000002951115,0.000141408,0.00006254687,0.007094891,0.0003207997,0.003589574,0.0001258261],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9311154,0.0517174,0.00004102911,0.006615295,0.004841855,0.003795069,0.00004064214,0.00003605632,0.001797256],"genre_scores_gemma":[0.986683,0.009894883,0.00005878463,0.001271706,0.001007154,0.0003037286,0.00002849258,0.00002098866,0.0007312307],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05556763,"threshold_uncertainty_score":0.6372133,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04493321513930112,"score_gpt":0.4229879946054951,"score_spread":0.3780547794661939,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}